COMP <GO>
NCI vs PG // EV/EBITDA & P/E VALUATION
Neo-Concept International Group Holdings Limited (Class A) (NASDAQ) VS. Procter & Gamble Company (NYSE) • 15-METRIC TALLY: NCI 1
— PG 11
▲ EV/EBITDA & P/E VALUATION LEADER: NCI
LAST: $0.71 (-2.16%) • MKT CAP: $6.6M
valuation
9.3x
LAST: $161.57 (+0.61%) • MKT CAP: $372.21B
valuation
16.2x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NCI VS. PG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NCI | PG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 51.20% | -14.30 | PG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.60% | 25.40% | -22.80 | PG | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 9.3x | 16.2x | -6.90 | NCI | /valuation <GO> |
| Free Cash Flow Yield | — | 3.77% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 1.30% | 24.30% | -23.00 | PG | /operating-margins <GO> |
| Net Profit Margin | 0.20% | 19.00% | -18.80 | PG | /net-margins <GO> |
| Revenue Growth (YoY) | -41.90% | 0.30% | -42.20 | PG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.65% | -2.65 | PG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.49 | 5.59 | -4.10 | PG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | PG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 18.3 | 60.3 | -42.00 | PG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.87 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 21.7x | +118.30 | PG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.6M | $372.21B | -$372.21B | PG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NCI REV | PG REV | NCI GROSS % | PG GROSS % | NCI FCF | PG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.6M | $84.28B | 36.9% | 51.2% | $2.2M | $14.04B |
| FY 2024 | $30.3M | $84.04B | 21.0% | 51.4% | -$478.4K | $16.52B |
| FY 2023 | $22.3M | $82.01B | — | — | -$6.3M | $13.16B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NCI // BETA —
PG // BETA 0.87